- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:18 | SANUWAVE Health GAAP EPS of -$0.08, revenue of $9.74M | 1 | Seeking Alpha | ||
| Do | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | SANUWAVE Health, Inc.: Sanuwave Announces Q2 FY2026 Financial Results | 70 | GlobeNewswire (Europe) | Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026... ► Artikel lesen | |
| Do | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.07. | Sanuwave sees Q2 revenue up to $9.8M | 1 | Seeking Alpha | ||
| SANUWAVE HEALTH Aktie jetzt für 0€ handeln | |||||
| 13.07. | Sanuwave: Q2-Umsatz übertrifft Prognose | 3 | Investing.com Deutsch | ||
| 13.07. | Sanuwave posts Q2 revenue of $9.6M-$9.8M, beating guidance | 1 | Investing.com | ||
| 13.07. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.07. | SANUWAVE Health, Inc.: Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6-$9.8 Million, Above High End of Revised Guidance | 992 | GlobeNewswire (Europe) | EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced... ► Artikel lesen | |
| 16.06. | SANUWAVE Health, Inc.: Sanuwave Health Updates Second Quarter 2026 Guidance | 202 | GlobeNewswire (Europe) | Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June... ► Artikel lesen | |
| 15.06. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | Sanuwave forecasts Q2 revenue of $11.1M-$11.6M while maintaining $51M-$55M full-year outlook | 1 | Seeking Alpha | ||
| 13.05. | SANUWAVE Health Inc Reports Q1 2026 Results: Full Earnings Call Transcript | 3 | Benzinga.com | ||
| 13.05. | SANUWAVE Health reports mixed Q1 results; initiates Q2 and reaffirms FY26 outlook | 2 | Seeking Alpha | ||
| 12.05. | SANUWAVE Health, Inc.: Sanuwave Announces Revenues and Financial Results for Q1 FY2026 | 212 | GlobeNewswire (Europe) | Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025.... ► Artikel lesen | |
| 12.05. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.04. | Sanuwave Health (SNWV) Slipped as CMS Dropped the Coverage Limit | 1 | Insider Monkey | ||
| 16.04. | Sanuwave reports Q1 revenue of $9.6M-$9.7M, up 3-4% year-over-year | 1 | Investing.com | ||
| 16.04. | Sanuwave meldet verlangsamtes Wachstum - Aktie unter Druck | 2 | Investing.com Deutsch |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,068 | -2,01 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA | Total revenue increased 60% year over year to $6.4 millionNet loss per share decreased 88% compared to the prior-year quarterGross margin expanded to 40% as operating expenses remained stableFDA clearance... ► Artikel lesen | |
| TANDEM DIABETES | 17,000 | +3,66 % | Tandem Diabetes Q2 2026 slides: PayGo model drives margin expansion | ||
| VERU | 2,295 | -0,65 % | Veru Inc.: Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss | ||
| SENSEONICS | 4,500 | +0,90 % | Senseonics outlines $62M-$66M 2026 revenue guidance as it raises gross margin target to 58%-61% | ||
| TEMPEST THERAPEUTICS | 0,902 | 0,00 % | Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T | Tempest's TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage... ► Artikel lesen | |
| VIRIDIAN THERAPEUTICS | 19,800 | +1,02 % | Viridian Therapeutics, Inc.\DE - 10-Q, Quarterly Report | ||
| SINTX TECHNOLOGIES | 1,630 | 0,00 % | SINTX Technologies, Inc.: SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program | SALT LAKE CITY, Utah, July 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a leader in advanced biomaterials and silicon nitride technologies for medical... ► Artikel lesen | |
| VYOME | 2,160 | +1,89 % | Mitschrift des Earnings Call: Vyome Holdings weist für Q1 2026 eine starke Cash-Position aus | ||
| VIVANI MEDICAL | 1,200 | +0,84 % | Vivani Medical, Inc.: Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management | Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1 trial is a Phase 1, randomized, controlled clinical trial design... ► Artikel lesen | |
| STEREOTAXIS | 1,148 | -1,71 % | Stereotaxis, Inc.: University of Szeged Pioneers First Robotic Cardiology Program in Hungary | First Robotic Magnetic Navigation system installed in HungaryUniversity of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac... ► Artikel lesen | |
| VIEMED HEALTHCARE | 7,900 | -3,66 % | Viemed Healthcare, Inc.: Viemed Healthcare Announces Second Quarter 2026 Financial Results | LAFAYETTE, LA / ACCESS Newswire / August 3, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic... ► Artikel lesen | |
| VIVOS THERAPEUTICS | 0,322 | +0,03 % | Vivos Therapeutics, Inc: Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology | LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing... ► Artikel lesen | |
| TENON MEDICAL | 0,168 | 0,00 % | Tenon Medical, Inc. Announces 1:35 Reverse Stock Split | LOS GATOS, CA / ACCESS Newswire / August 6, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic... ► Artikel lesen | |
| SEASTAR MEDICAL | 3,050 | 0,00 % | SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026 |
SANUWAVE HEALTH INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SANUWAVE HEALTH INC finden Sie auf Wallstreet Online.